ES2145286T3 - Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica. - Google Patents
Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica.Info
- Publication number
- ES2145286T3 ES2145286T3 ES95927228T ES95927228T ES2145286T3 ES 2145286 T3 ES2145286 T3 ES 2145286T3 ES 95927228 T ES95927228 T ES 95927228T ES 95927228 T ES95927228 T ES 95927228T ES 2145286 T3 ES2145286 T3 ES 2145286T3
- Authority
- ES
- Spain
- Prior art keywords
- gnrh
- antagonist
- dose
- southern
- gonadal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REGIMEN PARA EL CONTROL TERAPEUTICO DE UNA AFECCION DE CAUSA GONADAL-ESTEROIDEA EN LOS MAMIFEROS QUE SUPONE LA REDUCCION DEL SUMINISTRO ESTROGENICO MEDIANTE LA ADMINISTRACION DE UN ANTAGONISTA GNRH EN CANTIDAD SUFICIENTE PARA EVITAR LA PROLIFERACION DE TEJIDO ENDOMETRIAL SIN DETENER BASICAMENTE LA PRODUCCION ENDOGENA DE ESTROGENOS. METODO PARA DETERMINAR SI EL SUMINISTRO REDUCIDO DES ESTROGENOS EN UN INDIVIDUO EN EL QUE SE HA SUPRIMIDO LA CONCENTRACION DE ESTRADIOL HASTA LLEGAR A UN NIVEL OPTIMIZADO APROPIADO PARA EL MANEJO TERAPEUTICO DE LA AFECCION DE CAUSA GONADAL-ESTEROIDEA, COMO PUEDE SER LA ENDOMETRIOSIS, EN ESE INDIVIDUO MEDIANTE LA ADMINISTRACION DE UN ANTAGONISTA GNRH A UN NIVEL DE DOSIFICACION DADO QUE IMPLICA EL AJUSTE DE LA DOSIS, P.E. MEDIANTE LA PUESTA EN PRACTICA DE UN TEST DE PRUEBA DE PROGESTERONA Y DOSIS DE REGIMEN OPTIMAS DE UN ANTAGONISTA GNRH.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27959394A | 1994-07-22 | 1994-07-22 | |
| US08/467,860 US5658884A (en) | 1994-07-22 | 1995-06-06 | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2145286T3 true ES2145286T3 (es) | 2000-07-01 |
Family
ID=26959766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95927228T Expired - Lifetime ES2145286T3 (es) | 1994-07-22 | 1995-07-18 | Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0769956B1 (es) |
| JP (1) | JP3138477B2 (es) |
| CN (1) | CN1137722C (es) |
| AP (1) | AP775A (es) |
| AT (1) | ATE190494T1 (es) |
| AU (1) | AU691952B2 (es) |
| BG (1) | BG63363B1 (es) |
| BR (1) | BR9508718A (es) |
| CA (1) | CA2195745C (es) |
| CY (1) | CY2228B1 (es) |
| CZ (1) | CZ291803B6 (es) |
| DE (1) | DE69515666T2 (es) |
| DK (1) | DK0769956T3 (es) |
| EE (1) | EE03515B1 (es) |
| ES (1) | ES2145286T3 (es) |
| FI (1) | FI970244A (es) |
| GR (1) | GR3033590T3 (es) |
| HU (1) | HU218910B (es) |
| IL (1) | IL114655A (es) |
| IS (1) | IS4413A (es) |
| LV (1) | LV11823B (es) |
| MX (1) | MX9700574A (es) |
| NO (1) | NO970257L (es) |
| NZ (1) | NZ290554A (es) |
| OA (1) | OA10730A (es) |
| PT (1) | PT769956E (es) |
| RU (1) | RU2181598C2 (es) |
| SK (1) | SK282118B6 (es) |
| WO (1) | WO1996003138A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173592B1 (en) | 1999-03-31 | 2012-05-08 | Zentaris Ivf Gmbh | Method for a programmed controlled ovarian stimulation protocol |
| NZ534836A (en) * | 1999-09-23 | 2007-07-27 | Zentaris Gmbh | Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| GB0616111D0 (en) * | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
| EP2095818A1 (en) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| US20110129532A1 (en) * | 2008-05-29 | 2011-06-02 | Isr Immune System Regulation Ab | Method and means for treating viral disease, in particular hiv/aids |
| WO2016184829A1 (en) * | 2015-05-18 | 2016-11-24 | Nerre Therapeutics Limited | Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171835A (en) * | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| US5169932A (en) * | 1989-10-30 | 1992-12-08 | The Salk Institute For Biological Studies | Gnrh analogs |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
-
1995
- 1995-07-18 CN CNB951951696A patent/CN1137722C/zh not_active Expired - Fee Related
- 1995-07-18 NZ NZ290554A patent/NZ290554A/xx not_active IP Right Cessation
- 1995-07-18 EP EP95927228A patent/EP0769956B1/en not_active Revoked
- 1995-07-18 WO PCT/US1995/008996 patent/WO1996003138A1/en not_active Application Discontinuation
- 1995-07-18 DK DK95927228T patent/DK0769956T3/da active
- 1995-07-18 AU AU31320/95A patent/AU691952B2/en not_active Expired
- 1995-07-18 DE DE69515666T patent/DE69515666T2/de not_active Revoked
- 1995-07-18 RU RU97102759/14A patent/RU2181598C2/ru not_active IP Right Cessation
- 1995-07-18 ES ES95927228T patent/ES2145286T3/es not_active Expired - Lifetime
- 1995-07-18 HU HU9700046A patent/HU218910B/hu not_active IP Right Cessation
- 1995-07-18 BR BR9508718A patent/BR9508718A/pt not_active Application Discontinuation
- 1995-07-18 MX MX9700574A patent/MX9700574A/es unknown
- 1995-07-18 CZ CZ1997150A patent/CZ291803B6/cs not_active IP Right Cessation
- 1995-07-18 AT AT95927228T patent/ATE190494T1/de not_active IP Right Cessation
- 1995-07-18 SK SK70-97A patent/SK282118B6/sk not_active IP Right Cessation
- 1995-07-18 AP APAP/P/1997/000913A patent/AP775A/en active
- 1995-07-18 JP JP08505816A patent/JP3138477B2/ja not_active Expired - Lifetime
- 1995-07-18 PT PT95927228T patent/PT769956E/pt unknown
- 1995-07-18 IL IL11465595A patent/IL114655A/xx not_active IP Right Cessation
- 1995-07-18 CA CA002195745A patent/CA2195745C/en not_active Expired - Lifetime
- 1995-07-18 EE EE9700208A patent/EE03515B1/xx not_active IP Right Cessation
-
1997
- 1997-01-13 OA OA60952A patent/OA10730A/en unknown
- 1997-01-14 IS IS4413A patent/IS4413A/is unknown
- 1997-01-21 FI FI970244A patent/FI970244A/fi not_active Application Discontinuation
- 1997-01-21 BG BG101158A patent/BG63363B1/bg unknown
- 1997-01-21 NO NO970257A patent/NO970257L/no not_active Application Discontinuation
- 1997-02-26 LV LVP-97-30A patent/LV11823B/en unknown
-
2000
- 2000-05-31 GR GR20000401285T patent/GR3033590T3/el not_active IP Right Cessation
-
2001
- 2001-07-26 CY CY0100017A patent/CY2228B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2145286T3 (es) | Uso de un antagonista gnrh para la preparacion de una composicion farmaceutica. | |
| ES2132645T3 (es) | Uso en una composicion farmaceutica. | |
| NO20051545L (no) | Ostrogenerstatningsregime | |
| MX2022000279A (es) | Regimenes de antagonistas del receptor de estrogeno. | |
| PT799043E (pt) | Regime hormonal ciclofasico contendo antiprogestina e progestina | |
| ECSP055574A (es) | Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas. | |
| ES2190205T3 (es) | Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. | |
| JPS57501528A (es) | ||
| CL2022001692A1 (es) | Compuestos activos frente a receptores nucleares | |
| MX2017012991A (es) | Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito. | |
| AR062230A1 (es) | Aplicacion de dosis iniciales de analogos de lhrh y dosis de mantenimiento de antagonistas de lhrh para el tratamiento de canceres dependientes de hormonas y kits farmaceuticos correspondientes | |
| Razzaghdoust et al. | Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy | |
| MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
| DK1526856T3 (da) | Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi | |
| MX2023001571A (es) | Terapia combinada con antagonistas del receptor de adenosina. | |
| JO1879B1 (en) | Consolidation of the secretion of ovarian estrogen for prolonged treatment regimens | |
| AR044450A1 (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
| ES2173294T3 (es) | Nuevo uso medico. | |
| AR116592A1 (es) | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib | |
| CO5200773A1 (es) | Mesoprogestinas (moduladores de receptores para progestero- na) como componente de composiciones utilizadas para la terapia de sustitucion hormonal (trh) | |
| CO2024001947A2 (es) | Método para tratar la endometriosis y proporcionar una anticoncepción eficaz | |
| CO2022016665A2 (es) | Composiciones y métodos para suministrar agentes farmacéuticamente activos | |
| UY26539A1 (es) | Drospirenona para terapia de reemplazo de hormonas. | |
| TH35545A (th) | วิธีการบำบัดการขยายตัวผิดปกติของต่อมลูกหมากและมะเร็งของต่อมลูกหมาก | |
| ES2149985T3 (es) | Derivados imidazolilalquilo de imidazo(1,5-a)indol-3-ona y su uso como agentes terapeuticos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 769956 Country of ref document: ES |